Centrexion Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations at the 34th Annual American Academy of Pain Medicine Meeting

Company will present safety and tolerability data from Phase 1 clinical trial of CCR2 antagonist CNTX-6970 and 6-month efficacy and safety data from Phase 2b clinical trial of CNTX-4975 for treatment of moderate to severe osteoarthritis knee pain

BOSTON, Mass., April 19, 2018 -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced it will present Phase 1 safety and tolerability data of single ascending doses of CNTX-6970 in healthy volunteers and Phase 2b efficacy and safety data of CNTX-4975 for the treatment of moderate to severe osteoarthritis knee pain at the 34th Annual American Academy of Pain Medicine (AAPM) Meeting taking place April 25 - 29, 2018 at the Vancouver Convention Center in Vancouver, Canada.

Full abstracts are available online at http://www.painmed.org/2018scientific-abstracts/. Details of the poster presentations are listed below.

**Abstract Title:** Phase 1 Study of the Safety and Tolerability of Single Ascending Doses of the Novel Oral CCR2 Antagonist CNTX-6970 in Healthy Volunteers

**Session Title:** Basic Science

**Poster Number:** 111

**Presentation Time:** Thursday, April 26, 6:00-7:30 p.m. PDT

**Location:** AAPM Resource Center in the Vancouver Convention Center

**Title:** Efficacy and Safety of Intra-Articular CNTX-4975 (Highly Purified, Synthetic Trans-Capsaicin) in Subjects with Moderate to Severe Knee Pain Associated with Osteoarthritis: 24-Week Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study

**Session Title:** Basic Science

**Poster Number:** 112

**Presentation Time:** Thursday, April 26, 6:00-7:30 p.m. PDT

**Location:** AAPM Resource Center in the Vancouver Convention Center

**About Osteoarthritis**

Osteoarthritis (OA) is the most common form of arthritis, affecting approximately 14 million people in the United States. OA occurs when the protective cartilage on the ends of the bones wears down over time, and the bone around the joints harden and form edges. These changes cause pain, swelling and problems moving the joint. OA also causes an inflammatory process to occur in the affected joint, further damaging the cartilage. Although OA can damage the majority of joints in the body, it most commonly affects joints in the knees, hips, hands and spine. OA can cause pain severe enough that patients experience difficulty walking, climbing stairs or even rising from a chair. Despite currently available therapies, many patients opt for total joint replacement to manage the painful condition.

**About CNTX-6970**

CNTX-6970 is a novel, potent and selective CCR2 (C-C chemokine receptor type 2) antagonist with a unique analgesic profile. Recent studies have shown a close link between chronic pain and the immune system. CNTX-6970 capitalizes on this connection by taking a novel “neuro-immune” approach. The compound has a dual effect: stopping immune cells from releasing the potent cytokine MCP-1 (monocyte chemoattractant protein 1) and stopping MCP-1 from stimulating pain fibers to send pain signals. CNTX-6970 is predicted to be well suited to treat chronic painful inflammatory conditions, and a Phase 1 study
showed the treatment was well tolerated with demonstrated pharmacologic and pharmacodynamic activity.

About CNTX-4975
CNTX-4975 is based on Centrexion’s proprietary STRATI™ technology (Synthetic TRans cApsaicin ulTra-pure Injection), a highly potent, ultra-pure, synthetic form of trans-capsaicin. CNTX-4975 is designed to be injected directly into the site of pain to provide rapid onset, large reduction and long duration of relief from moderate to severe joint pain without affecting touch sensibility or position sense. CNTX-4975 works by targeting the capsaicin receptor (TRPV1) to selectively and rapidly inactivate the local pain fibers transmitting signals to the brain. With a short half-life, CNTX-4975 is cleared from the body within 24 hours. This approach is designed to provide pain relief that can last for months until the ends of the local pain fibers regenerate, while maintaining normal sensation, such as touch, pressure and position, and without the risks of toxicities of NSAIDs and injected corticosteroids, or the side effects, including abuse and addiction, associated with opioid treatments. In January 2018, CNTX-4975 was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of pain associated with knee osteoarthritis.

About Centrexion Therapeutics
Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest, exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion people living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. For more information about Centrexion Therapeutics, visit [http://www.centrexion.com](http://www.centrexion.com).


###

**Media Contact**
Julie Normart, W2O pure  
+1 (415) 946-1087  
jnormart@w2ogroup.com

**Investor Contact**
Courtney Dugan, W2O pure  
+1 (212) 257-6723  
cdugan@w2ogroup.com